Table 2.
Comparison of AUC ratios between water and lipid carrier solutions during HIPEC
| Anticancer drugs | Mitomycin-C | Oxaliplatin | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Carrier solutions | Dianeal® | Lipid solution | p value† | Dianeal® | 5% dextrose solution (5DW) | Lipid solution | p value†† | Post-hoc analysisa | ||
| p value (Dianeal vs. 5DW) | p value (Dianeal vs. lipid) | p value (5DW vs. lipid) | ||||||||
| AUCperitoneum | 159,209.3 ± 6843.8 | 188,918.4 ± 3341.9 | 0.003 | 1,671,286 ± 176,313.1 | 1,690,563 ± 411,394.1 | 1,594,976 ± 418,625.8 | 0.941 | 0.998 | 0.966 | 0.947 |
| AUCplasma | 7684.8 ± 575.4 | 3203.1 ± 46.4 | 0.005 | 95,540.1 ± 39,851.3 | 196,029.4 ± 47,823.8 | 78,824.3 ± 37,743.6 | 0.028 | 0.070 | 0.890 | 0.039 |
| AUC ratiob | 20.8 ± 1.6 | 59.0 ± 1.0 | < 0.001 | 19.3 ± 6.6 | 8.7 ± 1.6 | 22.2 ± 6.1 | 0.046 | 0.125 | 0.806 | 0.056 |
Bold values are statistically significant (p < 0.05)
†Independent t test
††One-way analysis of variances among groups (ANOVA)
aPost-hoc analysis was calculated by the Scheffe correction method
bAUCperitoneum/AUCplasma